Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
:PTN
RESEARCH TOOLSreports
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.53Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 1.01%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with significant achievements in reducing net loss and promising clinical trial results. However, challenges remain with the absence of product sales and a decrease in cash position. The company is actively pursuing strategic partnerships to enhance its future prospects.Company Guidance
During the second quarter fiscal year 2025 call, Palatin Technologies, Inc. provided guidance on several key metrics. They did not report any product sales for the quarter ended December 31, 2024, following the sale of worldwide rights for female sexual dysfunction to CoSette Pharmaceuticals in December 2023. Operating expenses were $2.6 million, net of a $2.5 million gain from the sale by lessee, compared to $0.9 million net of a $7.8 million gain for the same quarter in 2023. Net cash used in operations decreased to $4.8 million from $10.5 million in the previous year, while the net loss was reduced to $2.4 million from $7.8 million. As of December 31, 2024, cash and cash equivalents were $3.4 million, excluding $4.3 million raised in a February 2025 equity offering. Additionally, Palatin is actively seeking multiple funding sources for future operating cash requirements.Significant Decrease in Net Loss
Palatin Technologies, Inc.'s net loss for the quarter ended December 31, 2024, was $2.4 million compared to a net loss of $7.8 million for the same period in 2023.
Decrease in Net Cash Used in Operations
Net cash used in operations for the quarter ended December 31, 2024, was $4.8 million compared to $10.5 million for the same period in 2023.
Promising Phase 2 Breakout Study Results
71% of patients achieved a greater than 30% reduction in urinary protein to creatinine ratio and improved or stabilized estimated pulmonary filtration rate in a study for diabetic kidney disease.
Strategic Business Development
Significant increase in business development discussions for outlicensing and potential partnerships for the OPL 8177 and ocular melanocortin programs.
---
PTN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PTN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $0.99 | $1.06 | +7.07% |
| Nov 14, 2024 | $1.19 | $1.07 | -10.08% |
| Oct 01, 2024 | $0.89 | $0.88 | -1.12% |
| May 15, 2024 | $2.41 | $2.07 | -14.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Palatin Technologies Inc (PTN) report earnings?
Palatin Technologies Inc (PTN) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Palatin Technologies Inc (PTN) earnings time?
Palatin Technologies Inc (PTN) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTN EPS forecast?
PTN EPS forecast for the fiscal quarter 2025 (Q3) is -0.17.
---